The significant EPS miss reinforces the pre-revenue, clinical-stage risk profile. Traders should focus on upcoming DURIPANC data readouts (clinical benefit in Q1 2027, overall survival in Q3 2027) as the next major catalysts, while monitoring the cash burn rate against the $9.9M cash balance.
Price Chart
Executive Summary
AIM ImmunoTech reported Q2 2026 results with a net loss of $(3.8M) or $(0.43) per share, significantly missing the consensus estimate of $(0.12) per share. The company highlighted the completion of enrollment in its Phase 2 DURIPANC pancreatic cancer trial and a strengthened cash position of $9.9M, but the wider-than-expected loss and lack of revenue are the primary financial outcomes.
Key Financial Metrics
Key Facts
- Net loss of $(3.8M) or $(0.43) per share for Q2 2026, compared to $(2.8M) or $(3.68) per share in Q2 2025.
- EPS of $(0.43) missed the consensus estimate of $(0.12) by 258.3%.
- Cash and cash equivalents were $9.9M as of June 30, 2026, up from $3.0M at December 31, 2025.
- Completed patient enrollment and Ampligen dosing in the Phase 2 DURIPANC study for metastatic pancreatic cancer.
- Research and development expenses decreased to $589,000 from $1.2M year-over-year, while G&A expenses increased to $2.9M from $1.5M.
Financial Impact
Net loss of $(3.8M) for the quarter, with EPS of $(0.43) missing consensus by $0.31.
Risk Factors
- Pre-revenue biotech with no approved products and ongoing operating losses.
- Clinical trial risk: Phase 2 DURIPANC data may not meet endpoints, jeopardizing Phase 3 plans.
- Dilution risk: The company has a history of financing through debt and equity, and the $9.9M cash balance may not fully fund operations through key milestones.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-036753 |
| Exhibit: ex99-1.htm | 0001493152-26-036753 |
| Document: 0001493152-26-036753-index-headers.html | 0001493152-26-036753 |
| Document: 0001493152-26-036753-index.html | 0001493152-26-036753 |
| Document: 0001493152-26-036753.txt | 0001493152-26-036753 |
| 8-K Data (Synthetic) | 0001493152-26-036753 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers